Researchers Submit Patent Application, "Viral Vector-Based Gene Therapy For Ocular Conditions", for Approval (USPTO 20240132914).
In: Gene Therapy Weekly, 2024-05-13, S. 4237-4237
serialPeriodical
Zugriff:
A patent application has been submitted for a viral vector-based gene therapy for ocular conditions, specifically targeting glaucoma. Glaucoma affects millions of people worldwide and can lead to blindness due to the death of retinal ganglion cells. The gene therapy involves the use of recombinant adeno-associated viral vectors containing nucleic acid sequences encoding heat shock proteins, which can prevent or treat retinal damage by reducing the death of retinal ganglion cells. The therapy can be administered intravitreally and may have long-lasting effects. This information is based on a patent application filed by inventors Ram H. Nagaraj and Rooban B. Nahomi. [Extracted from the article]
Copyright of Gene Therapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Researchers Submit Patent Application, "Viral Vector-Based Gene Therapy For Ocular Conditions", for Approval (USPTO 20240132914).
|
---|---|
Zeitschrift: | Gene Therapy Weekly, 2024-05-13, S. 4237-4237 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1078-2842 (print) |
Schlagwort: |
|
Sonstiges: |
|